Petros Pharmaceuticals EBITDA Margin Growth & History (PTPI)

Petros Pharmaceuticals's ebitda margin was −35.13% for fiscal 2024.

View full Petros Pharmaceuticals company overview

Petros Pharmaceuticals annual ebitda margin history

Petros Pharmaceuticals annual ebitda margin

Fiscal yearPeriod endedEBITDA marginChange (percentage points)
20242024-12-31−35.13%+142.37 pp
20232023-12-31−177.49%+61.44 pp
20222022-12-31−238.93%−95.93 pp
20212021-12-31−143.00%−31.89 pp
20202020-12-31−111.11%

Petros Pharmaceuticals ebitda margin trends

Between the periods ended 2020-12-31 and 2024-12-31, Petros Pharmaceuticals's ebitda margin increased from −111.11% to −35.13%, a change of +75.98 percentage points. The latest reported quarter, Q4 2024, shows 10.83%.

About the metric

What EBITDA margin means

EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.

Calculation and source

How EBITDA margin is calculated

TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Petros Pharmaceuticals source filings ↗

Community posts

It’s quiet here.

No posts about PTPI yet. Start the conversation.

Write the first post